A Multicenter Global Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
Jaison Grimes, MD
Primary Investigator
Brief description of study
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: multiple sclerosis
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria
Patients with MS who have been newly prescribed DMF under routine clinical care are eligible to participate in the study.
Patients must be naive to DMF, Fumaderm and compounded fumarates at the time of enrollment, but need not be naive to other MS treatments, and must not be currently enrolled in any other clinical trial or study except for the DMF Pregnancy Registry or other studies that, according to the study Medical Director, do not conflict with the observational study (e.g., health economic studies)
Exclusion Criteria
Patients with previous exposure to DMF, Fumaderm, and compounded fumarates
Patients participating in other clinical studies